Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan
· Delayed Price · Currency is JPY 2,103.00
-38.50 (-1.80%)
At close: Dec 5, 2025
Ono Pharmaceutical Employees
Ono Pharmaceutical had 4,287 employees as of March 31, 2025. The number of employees increased by 434 or 11.26% compared to the previous year.
Employees
4,287
Change (1Y)
434
Growth (1Y)
11.26%
Revenue / Employee
117.49M JPY
Profits / Employee
11.31M JPY
Market Cap
988.22B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| HOYA Corporation | 37,909 |
| Takeda Pharmaceutical Company | 47,455 |
| Daiichi Sankyo Company | 19,765 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 13,643 |
| Shionogi & | 4,955 |
| Olympus | 29,297 |
Ono Pharmaceutical News
- 15 hours ago - Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting - Business Wire
- 20 days ago - Deciphera Announces the Opening of a New Office in Zug, Switzerland - Business Wire
- 24 days ago - Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025 - Business Wire
- 5 weeks ago - Ono Pharmaceutical reports Q2 results - Seeking Alpha
- 7 weeks ago - Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025 - Business Wire
- 2 months ago - Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy - Benzinga
- 2 months ago - Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) - Business Wire
- 4 months ago - Ono Pharmaceutical Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha